First Edition: August 17, 2010

August 22, 2015

"The tremendous increase in speed and cost-effectiveness the ABI SOLiD4 system provides is allowing us to dramatically accelerate development of the proprietary diagnostic databases and related information that are the foundation for our tests based on serum apoptotic DNA," said. Dr. Julia Beck, Laboratory Manager at Chronix. "The platform agnostic flexibility of our technology allows us to select the hardware with the optimal performance criteria, and results to date with this highly automated sequencer are very encouraging."

The Chronix approach has been validated in a number of peer-reviewed settings. In an oral presentation at the 2010 ASCO Annual Meeting, Chronix researchers presented data from 575 individuals showing that its assay detected breast cancer and invasive prostate cancer with 92% sensitivity and 100% specificity. These are encouraging results when compared to currently used early screening methods for these conditions. Additional published studies have demonstrated that the Chronix approach can identify the presence or absence of active disease in multiple sclerosis patients and that it can accurately detect early stage breast cancer with high diagnostic sensitivity and specificity.

Based on these encouraging findings, Chronix recently launched a "For Investigational Use Only" (IUO) testing service that enables cancer researchers to monitor the status of patients in their clinical trials with a high level of sensitivity and specificity. The new mass sequencer will allow for more rapid and cost-effective screening of large quantities of IOU samples, allowing Chronix to meet increasing demand for the service from clinical investigators while also conducting studies to expand its menu of tests.

Commercial applications for veterinary use of the Chronix technology, including tests for the early detection of BSE, or mad cow disease, are in development in conjunction with the University of Calgary

SOURCE Chronix Biomedical